Two of the largest drugmakers in the country are investing in a startup applying artificial intelligence in pathology. Boston-based PathAI said that it had closed its $75 million Series B financing round with funding from New York-based Bristol-Myers Squibb and
San Jose-based BrightInsight is a spin-off from contract manufacturer Flex and has raised funding for its internet-of-things platform for connected medical devices and drug delivery systems. Investors recently poured $25 million into BrightInsight that is looking to create a go-to
Halodoc, an online healthcare platform based in Indonesia, has secured additional funding from strategic investors including the Bill & Melinda Gates Foundation, Allianz X and Prudential. Allianz and Prudential provide insurance services in Indonesia and are users of Halodoc’s services.